trimetrexate glucuronate

trimetrexate glucuronate

NeuTrexin® An antimetabolic lipophilic dihydrofolate reductase inhibitor–ie, antifolate structurally related to MTX, which is antineoplastic and antimicrobial; TG is approved for treating PCP when Bactrim/Septra cannot be used in immunocompromised Pts, and in Pts with colorectal, gastric, and pancreatic CA, acute leukemia, osteosarcoma; it may enhance 5-FU effectiveness in 5-FU and leucovorin-based therapy, improving survival. See Pneumocystis carinii pneumonia.

trimetrexate glucuronate (trī´mi-trek´sāt´),

n brand name: Neutrexin;
drug class: folate antogonist;
action: inhibits the enzyme dihydrofolate reductase, which leads to interference with deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and protein synthesis in the
Pneumocystis carinii organism;
uses: alternative therapy for
P. carinii pneumonia in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS).
References in periodicals archive ?